Breaking News, Collaborations & Alliances

Boehringer, CureVac in Next Gen Immunotherapy Pact

Boehringer will conduct trials in advanced and unresectable NSCLC

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Boehringer Ingelheim and CureVac have entered an exclusive global license and development collaboration focused on CureVac’s CV9202, an investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer. CureVac’s mRNA-based technology represents a potential novel approach in cancer treatment mobilizing the patient’s own immune system to fight the tumor. Boehringer will begin clinical studies of CV9202 in combination with afatinib in patie...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters